ATE338565T1 - Verwendung eines antagonisten antikörpers gegen den entzündungsmediator oncostatin m (osm) - Google Patents

Verwendung eines antagonisten antikörpers gegen den entzündungsmediator oncostatin m (osm)

Info

Publication number
ATE338565T1
ATE338565T1 AT99911954T AT99911954T ATE338565T1 AT E338565 T1 ATE338565 T1 AT E338565T1 AT 99911954 T AT99911954 T AT 99911954T AT 99911954 T AT99911954 T AT 99911954T AT E338565 T1 ATE338565 T1 AT E338565T1
Authority
AT
Austria
Prior art keywords
osm
oncostatin
antibody against
antagonist antibody
inflammatory mediator
Prior art date
Application number
AT99911954T
Other languages
English (en)
Inventor
Paul Frederick Life
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE338565T1 publication Critical patent/ATE338565T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT99911954T 1998-03-26 1999-03-25 Verwendung eines antagonisten antikörpers gegen den entzündungsmediator oncostatin m (osm) ATE338565T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9806530.3A GB9806530D0 (en) 1998-03-26 1998-03-26 Inflammatory mediator

Publications (1)

Publication Number Publication Date
ATE338565T1 true ATE338565T1 (de) 2006-09-15

Family

ID=10829337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99911954T ATE338565T1 (de) 1998-03-26 1999-03-25 Verwendung eines antagonisten antikörpers gegen den entzündungsmediator oncostatin m (osm)

Country Status (20)

Country Link
US (5) US6706266B1 (de)
EP (2) EP1071449B1 (de)
JP (2) JP3825255B2 (de)
KR (1) KR20010034672A (de)
CN (1) CN1295482A (de)
AT (1) ATE338565T1 (de)
AU (1) AU3046399A (de)
BR (1) BR9909077A (de)
CA (1) CA2325585A1 (de)
CY (1) CY1105722T1 (de)
DE (1) DE69933115T2 (de)
DK (1) DK1071449T3 (de)
ES (1) ES2272058T3 (de)
GB (1) GB9806530D0 (de)
HU (1) HUP0101690A2 (de)
IL (1) IL138604A0 (de)
PL (1) PL343431A1 (de)
PT (1) PT1071449E (de)
WO (1) WO1999048523A2 (de)
ZA (1) ZA200005076B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
WO2001081345A1 (fr) * 2000-04-20 2001-11-01 Mitsubishi Pharma Corporation Composes d'amides aromatiques
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
US20060067938A1 (en) * 2001-10-26 2006-03-30 Sherif Daouti Methods for the treatment of osteoarthritis and compositions thereof
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1581169A4 (de) * 2002-11-08 2008-09-17 Genentech Inc Zusammensetzungen und verfahren zurbehandlung von erkrankungen in verbindung mit natürlichen killerzellen
JP4803789B2 (ja) * 2004-02-03 2011-10-26 独立行政法人科学技術振興機構 疼痛を処置するための薬学的組成物
KR100942849B1 (ko) * 2004-03-30 2010-02-17 글락소 그룹 리미티드 면역글로불린
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
WO2006035979A1 (ja) * 2004-09-29 2006-04-06 Asama Chemical Co., Ltd. 乳清タンパク、乳由来の抗体または抗体を含む機能性組成物または食品
EP1671642A1 (de) * 2004-12-15 2006-06-21 Universite D'angers Zusammensetzungen mit (Ant)agonisten von Oncostatin M (OSM), IL-31 und IFN-gamma zur Modulierung der Migration und Funktion von Keratinozyten via einen Rezeptor welcher OSMRbeta als Untereinheit enthält, und entprechende Anwendungen
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
US20060276440A1 (en) * 2005-01-03 2006-12-07 An Wenqian F Treatment of inflammatory disorders
ATE524546T1 (de) * 2005-03-25 2011-09-15 Medtronic Inc Verwendung von anti-tnf oder anti-il1-rnai zur unterdrückung der wirkung entzündungsfördernder cytokine zur lokalen schmerzbehandlung
US20090075342A1 (en) * 2005-04-26 2009-03-19 Sharon Cload Metabolic profile directed aptamer medicinal chemistry
US8354501B2 (en) * 2005-08-02 2013-01-15 Trustees Of Tufts College Methods for stepwise deposition of silk fibroin coatings
EP2173163A4 (de) * 2007-07-06 2010-12-08 Glaxosmithkline Llc Antikörperformulierungen
US8030290B2 (en) * 2007-12-07 2011-10-04 City Of Hope Cell-type specific aptamer-siRNA delivery system for HIV-1 Therapy
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
US8309688B2 (en) * 2008-12-30 2012-11-13 Centocor Ortho Biotech Inc. Monkey homolog of human oncostatin M and methods of use thereof
WO2010097386A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
WO2011080050A2 (en) 2009-12-11 2011-07-07 Novartis Ag Binding molecules
US8940303B2 (en) 2010-01-28 2015-01-27 Glaxo Group Limited CD127 binding proteins
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
ES2717908T3 (es) 2010-06-14 2019-06-26 Lykera Biomed S A Anticuerpos S100A4 y usos terapéuticos de los mismos
EP2627356B1 (de) 2010-10-13 2019-05-22 Janssen Biotech, Inc. Menschliche oncostatin-m-antikörper und verwendungsverfahren dafür
EP4029881A1 (de) 2010-11-08 2022-07-20 F. Hoffmann-La Roche AG Subkutan verabreichter anti-il-6-rezeptorantikörper
JP6351973B2 (ja) 2010-11-23 2018-07-04 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 抗原結合タンパク質
WO2013168829A1 (en) 2012-05-11 2013-11-14 Wakayama Medical University Anti oncostatin m receptor beta antibody
EA201592285A1 (ru) 2013-05-30 2016-05-31 Байоджен Ма Инк. Антигенсвязывающие белки к рецептору онкостатина м
EP3019199A4 (de) * 2013-07-09 2017-03-15 President and Fellows of Harvard College Mikrogefäss-endothelzellen-oberflächenmarker und verwendung davon
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US10203327B2 (en) 2013-11-05 2019-02-12 Novartis Ag Organic compounds
JP2014062100A (ja) * 2013-11-05 2014-04-10 Glaxosmithkline Llc 抗体処方
CN104096219A (zh) * 2014-07-08 2014-10-15 武汉大学 Ⅱ型抑瘤素m受体（osmr）在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
EP2985294A1 (de) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Rekombinantes Antikörpermolekül und dessen Verwendung zur zielzellenbeschränkten T-Zellen-Aktivierung
WO2016046738A1 (en) 2014-09-24 2016-03-31 Università Degli Studi Di Padova Composition to induce bone marrow stem cell mobilization
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
EP3250599B1 (de) * 2015-01-29 2021-04-14 Oxford University Innovation Limited Biomarker
GB201614627D0 (en) * 2016-08-30 2016-10-12 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
US11633457B2 (en) 2019-04-11 2023-04-25 Boise State University Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US646727A (en) * 1899-06-20 1900-04-03 Columbia Motor And Mfg Company Steam-generator.
US5681930A (en) * 1985-12-20 1997-10-28 Bristol-Myers Squibb Company Anti-oncostatin M monoclonal antibodies
US5618715A (en) * 1985-12-20 1997-04-08 Oncogen Limited Partnership Oncostatin M and novel compositions having anti-neoplastic activity
JPS6463395A (en) 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
IL94055A (en) 1989-04-10 1995-11-27 Oncogen Oncostatin M Container Pharmaceuticals to Change Tissue Immunogenicity and Improve Implant Absorption
US5814307A (en) 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
ES2120958T3 (es) 1989-12-08 1998-11-16 Bristol Myers Squibb Co Nuevas proteinas con actividad de oncostatina m y procedimiento para su preparacion.
IL97623A (en) * 1990-03-29 1996-01-19 Bristol Myers Squibb Co Monoclonal antibodies against oncostatin M, their preparation and pharmaceutical preparations containing them
DE4011684A1 (de) 1990-04-06 1991-10-10 Schering Ag Dtpa-monoamide, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
CA2055122A1 (en) 1990-11-13 1992-05-14 Robert I. Grove Methods for stimulating ldl uptake and ldl receptor expression
CA2116533A1 (en) 1991-08-30 1993-03-18 George J. Todaro Hybrid cytokines
US6171824B1 (en) 1991-08-30 2001-01-09 Fred Hutchinson Cancer Research Center Hybrid cytokines
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05304986A (ja) 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
US5744442A (en) 1992-08-26 1998-04-28 Bristol Meyers Squibb Company Regulation of cellular invasiveness
US5460810A (en) 1992-09-02 1995-10-24 Genetics Institute, Inc. Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11
IT1261787B (it) 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
FR2707882B1 (fr) 1993-07-23 1997-08-01 Immunotech Sa Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
US5451411A (en) 1993-10-15 1995-09-19 University Of Washington Methods and compositions for the oral delivery of therapeutic agents
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
GB9419021D0 (en) 1994-09-21 1994-11-09 Applied Research Systems Therapeutic protein
US5571513A (en) * 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
JPH09117288A (ja) 1995-06-06 1997-05-06 Bristol Myers Squibb Co オンコスタチンｍ誘導造血
WO1997016202A1 (en) 1995-10-27 1997-05-09 Amrad Operations Pty. Ltd. Cytokines and their use in treatment and/or prophylaxis of breast cancer
AU4669097A (en) 1996-10-25 1998-05-22 Bristol-Myers Squibb Company Oncostatin m for treating inflammation
US5958442A (en) * 1997-10-24 1999-09-28 Bristol-Myers Squibb Company Oncostatin M for treating inflammation
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator

Also Published As

Publication number Publication date
ZA200005076B (en) 2001-09-21
PL343431A1 (en) 2001-08-13
JP2002507580A (ja) 2002-03-12
WO1999048523A2 (en) 1999-09-30
US20040081650A1 (en) 2004-04-29
DE69933115D1 (de) 2006-10-19
US20060093602A1 (en) 2006-05-04
US6706266B1 (en) 2004-03-16
DK1071449T3 (da) 2007-01-02
US7291332B2 (en) 2007-11-06
DE69933115T2 (de) 2007-04-05
EP1849478A3 (de) 2013-05-29
BR9909077A (pt) 2000-12-05
CA2325585A1 (en) 1999-09-30
EP1071449B1 (de) 2006-09-06
HUP0101690A2 (hu) 2001-08-28
US8003101B2 (en) 2011-08-23
IL138604A0 (en) 2001-10-31
JP3825255B2 (ja) 2006-09-27
ES2272058T3 (es) 2007-04-16
WO1999048523A3 (en) 1999-11-25
US20080019967A1 (en) 2008-01-24
US20080044409A1 (en) 2008-02-21
KR20010034672A (ko) 2001-04-25
EP1071449A2 (de) 2001-01-31
AU3046399A (en) 1999-10-18
JP2006290893A (ja) 2006-10-26
PT1071449E (pt) 2006-12-29
EP1849478A2 (de) 2007-10-31
CY1105722T1 (el) 2010-12-22
GB9806530D0 (en) 1998-05-27
CN1295482A (zh) 2001-05-16

Similar Documents

Publication Publication Date Title
ATE338565T1 (de) Verwendung eines antagonisten antikörpers gegen den entzündungsmediator oncostatin m (osm)
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
EA200501274A1 (ru) Пиразолы и способы их получения и применения
EA200200530A1 (ru) Гетероциклические замещенные пиразолоны
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
EA200501724A1 (ru) Соединения, специфичные к меланокортиновым рецепторам
DK1017713T3 (da) Cykliske antagonister af C5a-receptorer og G-protein-koblede receptorer
DE69732868D1 (de) Mittel gegen Juckreiz
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
EA199800733A1 (ru) Антагонисты рецептора il-8
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
PT1353689E (pt) Composicoes imunizantes e metodos de utilizacao
EA200300593A1 (ru) Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора
ES2178676T3 (es) Compuestos de pirimidina substituidos y su empleo.
EA200301100A1 (ru) Новые фталазиноны
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
EA200500528A1 (ru) Пиперазинил- и диазапанилбензамиды и бензтиоамиды
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
EA200200732A1 (ru) Замещенные производные фенилпиперазина, их получение и применение
EA200000910A1 (ru) Азабициклические лиганды рецепторов 5нт1
EA200200727A1 (ru) Новые производные индола
DE60139770D1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1071449

Country of ref document: EP